- Home
- CSTL vs MEGI Comparison
CSTL vs MEGI Comparison
Compare CSTL & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- MEGI
- Stock Information
- Founded
- CSTL 2007
- MEGI 2021
- Country
- CSTL United States
- MEGI United States
- Employees
- CSTL N/A
- MEGI N/A
- Industry
- CSTL Medical Specialities
- MEGI Investment Managers
- Sector
- CSTL Health Care
- MEGI Finance
- Exchange
- CSTL Nasdaq
- MEGI Nasdaq
- Market Cap
- CSTL 661.7M
- MEGI 749.0M
- IPO Year
- CSTL 2019
- MEGI N/A
- Fundamental
- Price
- CSTL $22.14
- MEGI $14.93
- Analyst Decision
- CSTL Strong Buy
- MEGI
- Analyst Count
- CSTL 6
- MEGI 0
- Target Price
- CSTL $37.67
- MEGI N/A
- AVG Volume (30 Days)
- CSTL 296.4K
- MEGI 178.0K
- Earning Date
- CSTL 11-03-2025
- MEGI 01-01-0001
- Dividend Yield
- CSTL N/A
- MEGI 11.40%
- EPS Growth
- CSTL N/A
- MEGI N/A
- EPS
- CSTL N/A
- MEGI N/A
- Revenue
- CSTL $346,269,000.00
- MEGI N/A
- Revenue This Year
- CSTL N/A
- MEGI N/A
- Revenue Next Year
- CSTL N/A
- MEGI N/A
- P/E Ratio
- CSTL N/A
- MEGI N/A
- Revenue Growth
- CSTL 20.40
- MEGI N/A
- 52 Week Low
- CSTL $14.59
- MEGI $10.63
- 52 Week High
- CSTL $35.84
- MEGI $14.89
- Technical
- Relative Strength Index (RSI)
- CSTL 46.56
- MEGI 61.59
- Support Level
- CSTL $22.16
- MEGI $14.58
- Resistance Level
- CSTL $23.19
- MEGI $15.00
- Average True Range (ATR)
- CSTL 0.89
- MEGI 0.22
- MACD
- CSTL -0.16
- MEGI 0.00
- Stochastic Oscillator
- CSTL 10.05
- MEGI 79.33
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.